Thermo Fisher (TMO) balance sheet and financial health
TrendArc score 59 of 100 · Health 6.9 · Momentum 8.0 · Moat 5.7 · scored Nov 17, 2026 · How the score works
Cash and short-term investments less borrowings, September 26, 2026
$35.0 billion more borrowings than cash
Thermo Fisher held $6.1 billion of cash and short-term investments against $41.1 billion of borrowings on September 26, 2026. In the fiscal year to December 2025 its operating income covered its interest 5.5 times.
Borrowings to equity
0.75
$41.1B of borrowings on $54.8B of equity, Sep 2026
Interest cover
5.5x
operating income over interest, fiscal year to December 2025
Return on invested capital
7.3%
latest quarter to September 2026, annualised; the stock card's measure
Cash and borrowings at each fiscal year end
What the balance sheet holdsSeptember 26, 2026
"Other liabilities" is total liabilities less borrowings; "Property, goodwill and other" is total assets less the current assets and long-term investments; "Minority interests and other" is the rest of the funding (total assets less liabilities and shareholders' equity), mostly outside owners' stakes in subsidiaries.
Balance sheet, the last 10 fiscal year ends
| Fiscal year end | Latest Sep 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash and short-term investments | 6.1 | 10.1 | 5.6 | 8.1 | 8.5 | 4.5 | 10.3 | 2.4 | 2.1 | 1.3 | 0.8 |
| Receivables | 9.6 | 8.9 | 8.2 | 8.2 | 8.1 | 8.0 | 5.7 | 4.3 | 4.1 | 3.9 | 3.0 |
| Inventory | 5.6 | 5.4 | 5.0 | 5.1 | 5.6 | 5.1 | 4.0 | 3.4 | 3.0 | 3.0 | 2.2 |
| Other current assets | 4.3 | 4.3 | 3.4 | 3.2 | 3.0 | 2.6 | 1.9 | 1.8 | 1.4 | 1.2 | 1.0 |
| Total current assets | 25.6 | 28.7 | 22.1 | 24.6 | 25.2 | 20.1 | 22.0 | 11.9 | 10.6 | 9.4 | 7.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Total assets | 114.2 | 110.3 | 97.3 | 98.7 | 97.2 | 95.1 | 69.1 | 58.4 | 56.2 | 56.7 | 45.9 |
| Liabilities and equity | |||||||||||
| Current liabilities | 14.2 | 15.2 | 13.3 | 14.0 | 17.0 | 13.4 | 10.3 | 6.2 | 6.1 | 7.0 | 4.9 |
| Borrowings | 41.1 | 39.2 | 31.1 | 34.7 | 34.3 | 34.7 | 21.7 | 17.8 | 19.0 | 21.0 | 16.6 |
| Lease liabilities | — | 1.7 | 1.7 | 1.7 | 1.8 | 1.7 | 0.8 | 0.7 | — | — | — |
| Total liabilities | 59.5 | 56.9 | 47.8 | 52.0 | 53.1 | 54.3 | 34.5 | 28.7 | 28.6 | 31.3 | 24.4 |
| Shareholders' equity | 54.8 | 53.4 | 49.6 | 46.7 | 44.0 | 40.8 | 34.5 | 29.7 | 27.6 | 25.4 | 21.5 |
| Financial health | |||||||||||
| Cash less borrowings | -35.0 | -29.1 | -25.5 | -26.6 | -25.8 | -30.2 | -11.4 | -15.4 | -16.9 | -19.7 | -15.8 |
| Borrowings to equity | 0.75 | 0.73 | 0.63 | 0.74 | 0.78 | 0.85 | 0.63 | 0.60 | 0.69 | 0.83 | 0.77 |
| Interest cover | — | 5.5x | 5.3x | 5.0x | 11.6x | 18.7x | 14.1x | 6.8x | 5.7x | 5.0x | — |
Interest cover is operating income over interest expense, for full fiscal years. Minority interests and other is total assets less total liabilities and shareholders' equity (calculated by TrendArc). Company filings as standardised by Tiingo; borrowings and lease liabilities told apart with the lines the company files on SEC EDGAR, and a dash where the two cannot be told apart. Rebuilt nightly.
Thermo Fisher against its peers
| Company | Cash less borrowings | Borrowings to equity | Interest cover | Return on invested capital |
|---|---|---|---|---|
| Edwards LifesciencesEW | +$4.05B | 0.06 | 54.2x | 10.7% |
| Boston ScientificBSX | -$11.3B | 0.47 | 10.3x | 6.4% |
| StrykerSYK | -$11.7B | 0.64 | 8.1x | 8.0% |
| Becton DickinsonBDX | -$15.9B | 0.69 | 4.2x | 4.0% |
| MedtronicMDT | -$18.7B | 0.56 | 9.0x | 7.8% |
| DanaherDHR | -$20.8B | 0.49 | 17.7x | 6.3% |
| Abbott LaboratoriesABT | -$26.9B | 0.60 | 16.3x | 4.5% |
| Thermo FisherTMO | -$35.0B | 0.75 | 5.5x | 7.3% |
Each company's newest balance sheet; borrowings leave lease liabilities out; interest cover for its newest fiscal year; return on invested capital is the stock card's measure. A dash where a measure does not apply.
Next
Follow Thermo Fisher with a free account.
A watchlist, price alerts and saved chart layouts. No card needed.
Sign up freeNo forecast, no recommendation. This page describes Thermo Fisher from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Nov 17, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.
The TrendArc score, from 0 to 100, combines three pillars measured from published data, Health (business quality over the last twelve months), Momentum (the price against its moving averages, its 52-week high and the market) and Moat (durability over five years), with the share price's long-run trend. It describes the company as it stands today. It is not a forecast or a recommendation.